Affimed to Present at the Jefferies 2018 London Healthcare Conference
November 08 2018 - 5:35AM
Heidelberg, Germany, November 8, 2018 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies that harness the power of innate and adaptive
immunity (NK cells, macrophages and T cells), today announced that
Dr. Adi Hoess, CEO, will present at the Jefferies 2018 London
Healthcare Conference on Wednesday, November 14, 2018 at 8:40 am
GMT in London.
A live webcast of the conference presentation
can be accessed through the "Events" section on the "Investors
& Media" page of the Affimed website at
www.affimed.com/events.php. A replay of the presentation will be
available from Affimed's website for 30 days following the
conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK cells, macrophages and T
cells). We are developing single and combination therapies to treat
cancers and other life-threatening diseases. For more information,
please visit www.affimed.com.
Affimed Media Contact:Anca Alexandru,
Head of Communications, EU IRE-Mail: media@affimed.com
Affimed Investor Contact:Gregory Gin,
Head of Investor RelationsE-Mail: IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024